REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will distribute substantially all of the shares of the common stock of Codexis, Inc. (Nasdaq: CDXS) that it owns, as well as approximately $30.0 million in cash, by way of pro rata special distributions to Maxygen’s stockholders.
